Voyager Therapeutics, Inc.
VYGR
$3.17
-$0.26-7.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -173.80% | -161.15% | 65.08% | 54.34% | -109.13% |
| Total Depreciation and Amortization | -15.22% | -24.27% | 19.79% | 28.18% | 11.26% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.35% | 75.43% | 43.49% | 66.95% | 6.69% |
| Change in Net Operating Assets | -117.86% | 120.16% | -868.03% | -256.26% | 1,698.04% |
| Cash from Operations | -164.48% | 38.85% | -32.86% | -3,682.04% | -52.44% |
| Capital Expenditure | 69.27% | 79.47% | 67.01% | 20.08% | -320.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 144.57% | -198.04% | 141.02% | -49.13% | -726.16% |
| Cash from Investing | 142.89% | -201.38% | 140.65% | -45.74% | -762.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.93% | 24.78% | -95.77% | -63.11% | 260.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.93% | 24.78% | -95.77% | -63.11% | 260.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -95.52% | -1,264.96% | 120.33% | -179.55% | -55.39% |